30
Nov
2008
27
Apr
2008
Posted in I - Series B, Q - 1Q08, R - ROCKY MOUNTAIN, X - AMD, X - Asthma, X - Inflammation
Taligen Therapeutics (Aurora, CO) a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease closed a $65M Series B financing. Participants include Alta Partners, Clarus Ventures, Sanderling Ventures, Tango and High Country Venture.